2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 220-222
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transfusion, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, VWD, Genetic Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Young Adult
PAPER

877 Systemic bevacizumab for the treatment of severe bleeding and anemia in hereditary hemorrhagic telangiectasia (HHT): Primary results from the phase 2 trust-hht study

Hanny Al-Samkari, MD, Julia Keating, M.S.2, Nina Strojny, MS3, Neil Zakai, MD4, Josanna Rodriguez-Lopez, M.D.5, Rakesh Jain, PhD6, Lorene Pereira, RN7, Carolyn Donovan, B.S.8, Christos Belibasakis, B.S.9, Pamela Hodges, NP, PhD10, Debbie Jiang, M.D.11, Michael Pfeffer, MBBS12, Larissa Bornikova13, Katayoon Goodarzi, M.D.14, Rachel Rosovsky, MD, MPH15, Nicole Ciccolo, BS16, Catherine Elsier, MPH17, Nardeen Ayad, MBBS, MSc18, Jennifer Chase, BS19, Benjamin Bowman, BS20, Lalit Joshi, RPh21, Alexandra Mossali, RN22, Dan G. Duda, DMD, PhD23, David J Kuter, MD, DPhil24
1 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, United States
3 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
4 University of Vermont, Burlington, United States
5 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
6 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
9 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
10 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
11 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
12 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
13 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
14 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
15 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
16 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
17 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
18 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
19 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
20 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
21 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
22 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
23 Houston Methodist Academic Institute, Houston, United States
24 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States

BACKGROUND

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder (IBD) worldwide (1 in 5,000) and is the most morbid IBD of women. Severe, recurrent epistaxis, gastrointestinal (GI) bleeding, and organ arteriovenous malformations (AVMs) cause major morbidity and reduced survival. HHT has no licensed therapies worldwide. Bevacizumab (BEV), an anti-VEGF-A monoclonal antibody, is used off-label to treat bleeding in HHT based on only retrospective reports, limiting quantification of treatment benefit and adverse event (AE) assessment. Moreover, no data are available describing the impact of BEV on HRQoL or the treatment-associated dynamics of angiogenic biomarkers with HHT manifestations.

METHODS

TrUST-HHT (NCT04404881) was a U.S., NIH-funded, phase 2, open-label, investigator-initiated clinical trial of IV BEV in up to 33 adults with HHT and severe bleeding causing dependence on hematologic support (IV iron and/or RBC transfusion). Patients (pts) underwent a standardized Hematologic Support Protocol (HSP) for the entire study duration with q2 week labs and prespecified hemoglobin, ferritin, and transferrin saturation thresholds guiding IV iron/RBC transfusions and the quantities administered of each. After a 3-month Pretreatment Period used to calculate the 3-month Pretreatment Hematologic Support Score (HSS), pts entered a 3-month Induction Period (BEV 5 mg/kg q2 weeks) then a 3-month Maintenance Period (BEV 5 mg/kg q4 weeks). The HSS is a composite endpoint integrating RBC transfusions and iron infusions (HSS=RBC units transfused + [milligrams of elemental iron infused ÷ 250]) that reports hematologic support burden in red-cell unit equivalents (RUEs). The primary endpoint was the change in 3-month HSS from Pretreatment to Maintenance. Secondary endpoints included safety and changes in other hematologic parameters, Epistaxis Severity Score, and HRQoL from Pretreatment to Maintenance, as well as exploratory angiogenic biomarkers at 5 timepoints pre- and on-treatment.

RESULTS

Patients. 33 pts enrolled from 2019-2025, with median (range) age 60 (27-86) years; 55% female; 82% white, 15% Black, 10% Hispanic.

Primary Endpoint. BEV significantly reduced hematologic support requirements: mean change in 3-month HSS was –6.3 RUEs (95% CI –7.6, –5.1), P<0.001.

Secondary Efficacy Endpoints. Mean hemoglobin increased by +3.1 g/dL (95% CI 2.4, 3.8), P<0.001. Median IV iron infused decreased from 1620 mg (range 510-3060) Pretreatment to 510 mg (range 0-2550) at Maintenance, P<0.001. Median RBC transfusions decreased from 0 units (range 0-7) during Pretreatment to 0 units (range, 0-0) at Maintenance, P=0.006. Epistaxis Severity Score improved by –2.3 points (95% CI –2.8, –1.7), P<0.001. The HHT-Specific Quality of Life Scale (validated HHT HRQoL instrument, 0-16 points, minimal important difference of 1.1 points) score improved (median change −4.0 points, IQR −5.1 to −1.4, P<0.001). General HRQoL also significantly improved in all 3 PROMIS instruments used.

Safety. The most common treatment-emergent AEs (TEAEs) were hypertension in 19 pts (58%; 2 pts grade 1, 14 grade 2, 3 grade 3), arthralgia/myalgia in 14 (42%; resulted in BEV discontinuation in 1 pt), and headache in 8 (24%). Grade 3+ TEAEs occurred in 7 pts (21%).

Biomarker Analyses. Plasma bFGF, sVEGFR1, VEGF-A, and Ang-2 decreased significantly after BEV treatment, while PlGF increased. Changes in HSS correlated with changes in VEGF-C (rho= –0.43, P=0.03), VEGF-D (rho= –0.43, P=0.028), and bFGF (rho=0.45, P=0.021), suggesting treatment-associated remodeling of angiogenic signaling. Baseline HSS was correlated with pretreatment VEGF-D (rho=0.50, P=0.003) and Ang2 (rho=0.37, P=0.032).

CONCLUSIONS

In this first prospective, adequately powered, NIH-funded clinical trial of BEV for bleeding in HHT and first prospective trial of a chronic bleeding disorder to utilize a rigorous HSP with a composite hematologic endpoint (HSS), BEV was efficacious in treating bleeding and anemia along with significant improvements in disease-specific and general HRQoL. TEAEs—particularly hypertension and arthralgia/myalgia—were notably more frequent than reported in retrospective studies. Finally, exploratory biomarker analyses indicated BEV-associated angiogenic remodeling and hypothesis-generating mechanistic insight that merits further validation. The Ang2-HSS correlation is particularly interesting and may reflect compensatory angiogenic signaling in HHT.

Hanny Al-Samkari, MD: Atavistik - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; SOBI - Research Funding; Novartis - Research Funding; Alnylam - Research Funding; Vaderis - Research Funding; Tectonic - Research Funding; Argenx - Research Funding; Agios Pharmaceuticals - Research Funding; Alpine Immune Sciences - Research Funding; Pharmacosmos - Research Funding; Novartis - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Tectonic - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Diagonal - Consultancy (Includes expert testimony); Terremoto - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Atavistik - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)